Yet, the current study did not assess the influence of CIN-dependent cGAS–STING signaling activity in EGFR-mutated NSCLC on the tumor immune environment or the efficacy of EGFR-TKI therapy. This evidence concerns the gene STING1 and non-small cell lung carcinoma.